title: IFN-γ and TNF-α potentiate prostaglandin D2-induced human eosinophil chemotaxis through up-regulation of CRTH2 surface receptor.
abstract: Prostaglandin D2 (PGD2) receptor CRTH2, is a pro-inflammatory molecule involved in eosinophil recruitment to the allergic airway. We investigated the expression of CRTH2 in eosinophil from allergic rhinitis patients (AR) and tested the modulatory role of several TH1 and TH2 cytokines closely related to the allergic immunological response, on the expression of CRTH2 receptor, utilizing human eosinophil cell line (Eol-1).The expression of CRTH2 was tested by immunohistochemistry and flow cytometry (FACS). Chemotaxis was performed in micro-chemotaxis chambers. It is shown that the expression of CRTH2 by eosinophils was significantly higher in the nasal tissue and peripheral blood of AR patients, when compared to control subjects. PGD2 exhibited a typical bell shape dose response in attracting eosinophil from AR patients with optimal activity at 10(-7) M. Eol-1 cell surface expression of CRTH2 was significantly up-regulated by 10 ng/ml IFN-γ and TNF-α. The percentage of Eol-1 cells expressing the receptor increased by IFN-γ and TNF-α from 12.74%±2.66 to 55%±8 and 33.8%±9.4, respectively. PGD2-induced Eol-1 chemotaxis was not blocked by SB203580, H-89 Dihydrochloride, Bisindo-lylmaleimide, or Genistein. PGD2-induced Eol-1 chemotaxis was potentiated by IFN-γ and TNF-α without changing the signal transduction pathway. Correlation of our results to peripheral blood eosinophils from allergic rhinitis patients confirmed that 3 hour pretreatment of eosinophils by 10 ng/ml IFN-γ and TNF-α, increased the mean fluorescence intensity (MFI) of CRTH2 from 8.23 to 9.68 and 9.38, respectively, and potentiated PGD2-induced eosinophil chemotaxis. Our results demonstrate a novel synergism between PGD2, IFN-γ and TNF-α, in eosinophil chemotaxis.
authors.affiliation: Department of Oto-Rhino-Laryngology and Head and Neck Surgery, GIGA-Research, Liege University Hospitals (Centre Hospitalier Universaitaire), Liege, Belgium. amrel_shazly@hotmail.com
authors.forename: A E
authors.initials: AE
authors.lastname: El-Shazly
authors.forename: V
authors.initials: V
authors.lastname: Moonen
authors.forename: M
authors.initials: M
authors.lastname: Mawet
authors.forename: D
authors.initials: D
authors.lastname: Begon
authors.forename: M
authors.initials: M
authors.lastname: Henket
authors.forename: M
authors.initials: M
authors.lastname: Arafa
authors.forename: R
authors.initials: R
authors.lastname: Louis
authors.forename: P
authors.initials: P
authors.lastname: Delvenne
authors.forename: P P
authors.initials: PP
authors.lastname: Lefebvre
mesh_terms: D015153:Blotting, Western; D016022:Case-Control Studies; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D002634:Chemotaxis, Leukocyte / Q000187:drug effects*; D004306:Dose-Response Relationship, Immunologic; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000276:immunology / Q000494:pharmacology*; D009297:Nasal Mucosa / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D015230:Prostaglandin D2 / Q000494:pharmacology*; D011971:Receptors, Immunologic / Q000096:biosynthesis* / Q000276:immunology; D011982:Receptors, Prostaglandin / Q000096:biosynthesis* / Q000276:immunology; D012221:Rhinitis, Allergic, Perennial / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000494:pharmacology*; D015854:Up-Regulation
chemical_list: D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D015230:Prostaglandin D2; C036293:prostaglandin D2 receptor